Relmada shareholders reject equity plan increase and say-on-pay at annual meeting

RELMADA THERAPEUTICS, INC.

Director John Glasspool received 7.7M for and 9.98M withheld; Paul Kelly had 11.8M for, 5.88M withheld.
Ratification of Marcum LLP as auditor approved: 19.98M for, 1.97M against.
Proposal to increase 2021 Equity Plan by 4.5M shares failed: 4.26M for, 13.41M against.
Advisory vote on executive compensation did not pass: 7.53M for, 10.12M against.
72.9% of outstanding shares (21.99M of 30.17M) were present at the meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.